155 related articles for article (PubMed ID: 37899129)
1. Impact of
Magahis PT; Maron SB; Cowzer D; King S; Schattner M; Janjigian Y; Faleck D; Laszkowska M
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899129
[TBL] [Abstract][Full Text] [Related]
2. Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
Che H; Xiong Q; Ma J; Chen S; Wu H; Xu H; Hou B
BMC Cancer; 2022 Aug; 22(1):904. PubMed ID: 35986342
[TBL] [Abstract][Full Text] [Related]
3. Impact of
Yu B; Peppelenbosch M; Fuhler G
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38242721
[No Abstract] [Full Text] [Related]
4.
Tonneau M; Nolin-Lapalme A; Kazandjian S; Auclin E; Panasci J; Benlaifaoui M; Ponce M; Al-Saleh A; Belkaid W; Naimi S; Mihalcioiu C; Watson I; Bouin M; Miller W; Hudson M; Wong MK; Pezo RC; Turcotte S; Bélanger K; Jamal R; Oster P; Velin D; Richard C; Messaoudene M; Elkrief A; Routy B
Oncoimmunology; 2022; 11(1):2096535. PubMed ID: 35832043
[TBL] [Abstract][Full Text] [Related]
5. Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.
Zhang MJ; Chen DS; Li S; Chen L; Qi YX; Zhang CJ
Invest New Drugs; 2021 Oct; 39(5):1436-1438. PubMed ID: 33913072
[TBL] [Abstract][Full Text] [Related]
6. Impact of
Noori M; Fayyaz F; Rezaei N
Immunotherapy; 2023 Jun; 15(9):657-667. PubMed ID: 37140002
[TBL] [Abstract][Full Text] [Related]
7.
Oster P; Vaillant L; Riva E; McMillan B; Begka C; Truntzer C; Richard C; Leblond MM; Messaoudene M; Machremi E; Limagne E; Ghiringhelli F; Routy B; Verdeil G; Velin D
Gut; 2022 Mar; 71(3):457-466. PubMed ID: 34253574
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population.
Nguyen TH; Mallepally N; Hammad T; Liu Y; Thrift AP; El-Serag HB; Tan MC
Dig Dis Sci; 2020 Aug; 65(8):2403-2411. PubMed ID: 31728790
[TBL] [Abstract][Full Text] [Related]
9. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
10. Helicobacter pylori Infection as a Predictor of Treatment Outcomes of Gastric Cancer: A Systematic Review and Meta-Analysis.
Gan C; Wu X; Shen Y; Cao Z; Jing J; Pan W
Dig Dis; 2023; 41(4):553-564. PubMed ID: 36907179
[TBL] [Abstract][Full Text] [Related]
11. Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with S-1 adjuvant chemotherapy.
Nishizuka SS; Tamura G; Nakatochi M; Fukushima N; Ohmori Y; Sumida C; Iwaya T; Takahashi T; Koeda K;
J Surg Oncol; 2018 Apr; 117(5):947-956. PubMed ID: 29355977
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of helicobacter pylori-infection in gastric diffuse large B-cell lymphoma.
Cheng Y; Xiao Y; Zhou R; Liao Y; Zhou J; Ma X
BMC Cancer; 2019 Aug; 19(1):842. PubMed ID: 31455250
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori infection as an independent prognostic factor for locally advanced gastric cancer patients treated with adjuvant chemotherapy after curative resection.
Kang SY; Han JH; Ahn MS; Lee HW; Jeong SH; Park JS; Cho YK; Han SU; Kim YB; Kim JH; Sheen SS; Lim HY; Choi JH
Int J Cancer; 2012 Feb; 130(4):948-58. PubMed ID: 21425257
[TBL] [Abstract][Full Text] [Related]
14. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
15. Negative Helicobacter pylori status is associated with poor prognosis in patients with gastric cancer.
Marrelli D; Pedrazzani C; Berardi A; Corso G; Neri A; Garosi L; Vindigni C; Santucci A; Figura N; Roviello F
Cancer; 2009 May; 115(10):2071-80. PubMed ID: 19280589
[TBL] [Abstract][Full Text] [Related]
16. Preoperative Helicobacter pylori Infection is Associated with Increased Survival After Resection of Gastric Adenocarcinoma.
Postlewait LM; Squires MH; Kooby DA; Poultsides GA; Weber SM; Bloomston M; Fields RC; Pawlik TM; Votanopoulos KI; Schmidt CR; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Swords D; Jin LX; Cho CS; Winslow ER; Cardona K; Staley CA; Maithel SK
Ann Surg Oncol; 2016 Apr; 23(4):1225-33. PubMed ID: 26553442
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori infection reduces the efficacy of cancer immunotherapy: A systematic review and meta-analysis.
Gong X; Shen L; Xie J; Liu D; Xie Y; Liu D
Helicobacter; 2023 Dec; 28(6):e13011. PubMed ID: 37661590
[TBL] [Abstract][Full Text] [Related]
18. Positive H. pylori status predicts better prognosis of non-cardiac gastric cancer patients: results from cohort study and meta-analysis.
Jia Z; Zheng M; Jiang J; Cao D; Wu Y; Zhang Y; Fu Y; Cao X
BMC Cancer; 2022 Feb; 22(1):155. PubMed ID: 35135494
[TBL] [Abstract][Full Text] [Related]
19. Gastric cancer patients with Helicobacter pylori infection have a poor prognosis.
Li G; Wang Z; Wang Z; Xu J; Cui J; Cai S; Zhan W; He Y
J Surg Oncol; 2013 Dec; 108(7):421-6. PubMed ID: 24037736
[TBL] [Abstract][Full Text] [Related]
20. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics.
Yoon H; Kim N; Lee HS; Shin CM; Park YS; Lee DH; Jung HC; Song IS
Helicobacter; 2011 Oct; 16(5):382-8. PubMed ID: 21923684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
